Logo image of IUI1.DE

INTUITIVE SURGICAL INC (IUI1.DE) Stock Fundamental Analysis

FRA:IUI1 - Deutsche Boerse Ag - US46120E6023 - Common Stock - Currency: EUR

438.25  -12.3 (-2.73%)

Fundamental Rating

7

IUI1 gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 57 industry peers in the Health Care Equipment & Supplies industry. IUI1 scores excellent points on both the profitability and health parts. This is a solid base for a good stock. IUI1 is valued quite expensive, but it does show an excellent growth. These ratings could make IUI1 a good candidate for growth and quality investing.


Dividend Valuation Growth Profitability Health

Quickly go to:

8

1. Profitability

1.1 Basic Checks

In the past year IUI1 was profitable.
In the past year IUI1 had a positive cash flow from operations.
IUI1 had positive earnings in each of the past 5 years.
IUI1 had a positive operating cash flow in each of the past 5 years.
IUI1.DE Yearly Net Income VS EBIT VS OCF VS FCFIUI1.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

1.2 Ratios

IUI1 has a Return On Assets of 12.88%. This is amongst the best in the industry. IUI1 outperforms 91.23% of its industry peers.
With an excellent Return On Equity value of 14.47%, IUI1 belongs to the best of the industry, outperforming 80.70% of the companies in the same industry.
IUI1 has a Return On Invested Capital of 9.81%. This is amongst the best in the industry. IUI1 outperforms 82.46% of its industry peers.
IUI1 had an Average Return On Invested Capital over the past 3 years of 9.61%. This is in line with the industry average of 8.12%.
The 3 year average ROIC (9.61%) for IUI1 is below the current ROIC(9.81%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 12.88%
ROE 14.47%
ROIC 9.81%
ROA(3y)11.41%
ROA(5y)11.26%
ROE(3y)13.18%
ROE(5y)12.95%
ROIC(3y)9.61%
ROIC(5y)9.32%
IUI1.DE Yearly ROA, ROE, ROICIUI1.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5 10 15

1.3 Margins

Looking at the Profit Margin, with a value of 28.41%, IUI1 belongs to the top of the industry, outperforming 94.74% of the companies in the same industry.
IUI1's Profit Margin has declined in the last couple of years.
Looking at the Operating Margin, with a value of 28.28%, IUI1 belongs to the top of the industry, outperforming 98.25% of the companies in the same industry.
IUI1's Operating Margin has declined in the last couple of years.
IUI1 has a better Gross Margin (67.09%) than 73.68% of its industry peers.
IUI1's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 28.28%
PM (TTM) 28.41%
GM 67.09%
OM growth 3Y-4.3%
OM growth 5Y-1.74%
PM growth 3Y-2.34%
PM growth 5Y-2.02%
GM growth 3Y-0.91%
GM growth 5Y-0.58%
IUI1.DE Yearly Profit, Operating, Gross MarginsIUI1.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60

More info and screens

9

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so IUI1 is still creating some value.
Compared to 1 year ago, IUI1 has more shares outstanding
IUI1 has more shares outstanding than it did 5 years ago.
There is no outstanding debt for IUI1. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
IUI1.DE Yearly Shares OutstandingIUI1.DE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M
IUI1.DE Yearly Total Debt VS Total AssetsIUI1.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

2.2 Solvency

An Altman-Z score of 53.86 indicates that IUI1 is not in any danger for bankruptcy at the moment.
IUI1 has a better Altman-Z score (53.86) than 100.00% of its industry peers.
There is no outstanding debt for IUI1. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 53.86
ROIC/WACC1.08
WACC9.07%
IUI1.DE Yearly LT Debt VS Equity VS FCFIUI1.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

2.3 Liquidity

A Current Ratio of 4.98 indicates that IUI1 has no problem at all paying its short term obligations.
The Current ratio of IUI1 (4.98) is better than 94.74% of its industry peers.
IUI1 has a Quick Ratio of 3.97. This indicates that IUI1 is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of IUI1 (3.97) is better than 94.74% of its industry peers.
Industry RankSector Rank
Current Ratio 4.98
Quick Ratio 3.97
IUI1.DE Yearly Current Assets VS Current LiabilitesIUI1.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B 10B

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 27.76% over the past year.
The Earnings Per Share has been growing by 11.48% on average over the past years. This is quite good.
IUI1 shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 19.08%.
The Revenue has been growing by 13.27% on average over the past years. This is quite good.
EPS 1Y (TTM)27.76%
EPS 3Y13.83%
EPS 5Y11.48%
EPS Q2Q%20.67%
Revenue 1Y (TTM)19.08%
Revenue growth 3Y13.51%
Revenue growth 5Y13.27%
Sales Q2Q%19.19%

3.2 Future

IUI1 is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.45% yearly.
The Revenue is expected to grow by 14.12% on average over the next years. This is quite good.
EPS Next Y9.11%
EPS Next 2Y12.18%
EPS Next 3Y13.89%
EPS Next 5Y14.45%
Revenue Next Year18.04%
Revenue Next 2Y16.59%
Revenue Next 3Y16.13%
Revenue Next 5Y14.12%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
IUI1.DE Yearly Revenue VS EstimatesIUI1.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 5B 10B 15B 20B
IUI1.DE Yearly EPS VS EstimatesIUI1.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 5 10 15

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 67.01, the valuation of IUI1 can be described as expensive.
Compared to the rest of the industry, the Price/Earnings ratio of IUI1 is on the same level as its industry peers.
When comparing the Price/Earnings ratio of IUI1 to the average of the S&P500 Index (27.41), we can say IUI1 is valued expensively.
The Price/Forward Earnings ratio is 55.50, which means the current valuation is very expensive for IUI1.
Based on the Price/Forward Earnings ratio, IUI1 is valued a bit more expensive than 63.16% of the companies in the same industry.
IUI1 is valuated expensively when we compare the Price/Forward Earnings ratio to 35.19, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 67.01
Fwd PE 55.5
IUI1.DE Price Earnings VS Forward Price EarningsIUI1.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, IUI1 is valued a bit more expensive than the industry average as 66.67% of the companies are valued more cheaply.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of IUI1 is on the same level as its industry peers.
Industry RankSector Rank
P/FCF 105.15
EV/EBITDA 59.02
IUI1.DE Per share dataIUI1.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates IUI1 does not grow enough to justify the current Price/Earnings ratio.
The excellent profitability rating of IUI1 may justify a higher PE ratio.
A more expensive valuation may be justified as IUI1's earnings are expected to grow with 13.89% in the coming years.
PEG (NY)7.36
PEG (5Y)5.84
EPS Next 2Y12.18%
EPS Next 3Y13.89%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for IUI1!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INTUITIVE SURGICAL INC

FRA:IUI1 (7/11/2025, 7:00:00 PM)

438.25

-12.3 (-2.73%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)04-22 2025-04-22/amc
Earnings (Next)07-22 2025-07-22/amc
Inst Owners88.74%
Inst Owner ChangeN/A
Ins Owners0.45%
Ins Owner ChangeN/A
Market Cap157.08B
Analysts78.97
Price Target519.06 (18.44%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.91%
Min EPS beat(2)3.05%
Max EPS beat(2)20.76%
EPS beat(4)4
Avg EPS beat(4)11.89%
Min EPS beat(4)3.05%
Max EPS beat(4)20.76%
EPS beat(8)8
Avg EPS beat(8)8.01%
EPS beat(12)10
Avg EPS beat(12)4.94%
EPS beat(16)13
Avg EPS beat(16)5.44%
Revenue beat(2)2
Avg Revenue beat(2)3.11%
Min Revenue beat(2)1.09%
Max Revenue beat(2)5.12%
Revenue beat(4)2
Avg Revenue beat(4)1.5%
Min Revenue beat(4)-0.14%
Max Revenue beat(4)5.12%
Revenue beat(8)3
Avg Revenue beat(8)0.14%
Revenue beat(12)5
Avg Revenue beat(12)-0.1%
Revenue beat(16)7
Avg Revenue beat(16)0.86%
PT rev (1m)-0.84%
PT rev (3m)-11.99%
EPS NQ rev (1m)-0.05%
EPS NQ rev (3m)-2.05%
EPS NY rev (1m)0.25%
EPS NY rev (3m)-2.52%
Revenue NQ rev (1m)0.13%
Revenue NQ rev (3m)0.38%
Revenue NY rev (1m)-0.04%
Revenue NY rev (3m)0.64%
Valuation
Industry RankSector Rank
PE 67.01
Fwd PE 55.5
P/S 21.06
P/FCF 105.15
P/OCF 67.19
P/B 10.73
P/tB 10.96
EV/EBITDA 59.02
EPS(TTM)6.54
EY1.49%
EPS(NY)7.9
Fwd EY1.8%
FCF(TTM)4.17
FCFY0.95%
OCF(TTM)6.52
OCFY1.49%
SpS20.81
BVpS40.85
TBVpS39.98
PEG (NY)7.36
PEG (5Y)5.84
Profitability
Industry RankSector Rank
ROA 12.88%
ROE 14.47%
ROCE 13.94%
ROIC 9.81%
ROICexc 13.3%
ROICexgc 13.69%
OM 28.28%
PM (TTM) 28.41%
GM 67.09%
FCFM 20.03%
ROA(3y)11.41%
ROA(5y)11.26%
ROE(3y)13.18%
ROE(5y)12.95%
ROIC(3y)9.61%
ROIC(5y)9.32%
ROICexc(3y)17.26%
ROICexc(5y)16.59%
ROICexgc(3y)18.14%
ROICexgc(5y)17.56%
ROCE(3y)13.65%
ROCE(5y)13.23%
ROICexcg growth 3Y10.09%
ROICexcg growth 5Y3.3%
ROICexc growth 3Y10.33%
ROICexc growth 5Y3.99%
OM growth 3Y-4.3%
OM growth 5Y-1.74%
PM growth 3Y-2.34%
PM growth 5Y-2.02%
GM growth 3Y-0.91%
GM growth 5Y-0.58%
F-Score6
Asset Turnover0.45
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 185.49%
Cap/Sales 11.31%
Interest Coverage 250
Cash Conversion 91.16%
Profit Quality 70.49%
Current Ratio 4.98
Quick Ratio 3.97
Altman-Z 53.86
F-Score6
WACC9.07%
ROIC/WACC1.08
Cap/Depr(3y)197.35%
Cap/Depr(5y)162.98%
Cap/Sales(3y)12.27%
Cap/Sales(5y)10.16%
Profit Quality(3y)56.77%
Profit Quality(5y)75.99%
High Growth Momentum
Growth
EPS 1Y (TTM)27.76%
EPS 3Y13.83%
EPS 5Y11.48%
EPS Q2Q%20.67%
EPS Next Y9.11%
EPS Next 2Y12.18%
EPS Next 3Y13.89%
EPS Next 5Y14.45%
Revenue 1Y (TTM)19.08%
Revenue growth 3Y13.51%
Revenue growth 5Y13.27%
Sales Q2Q%19.19%
Revenue Next Year18.04%
Revenue Next 2Y16.59%
Revenue Next 3Y16.13%
Revenue Next 5Y14.12%
EBIT growth 1Y32.36%
EBIT growth 3Y8.64%
EBIT growth 5Y11.3%
EBIT Next Year33.95%
EBIT Next 3Y22.85%
EBIT Next 5Y19.86%
FCF growth 1Y73.18%
FCF growth 3Y-9.1%
FCF growth 5Y2.14%
OCF growth 1Y66.62%
OCF growth 3Y4.95%
OCF growth 5Y8.61%